Medications like donanemab (Kisunla) and lecanemab (Leqembi) target amyloid plaques that build up in the brain due to ...

The a-secretase cleavage site lies within the amyloid-beta peptide associated with Alzheimer plaques. Therefore, an increase in asecretase activity has been found to be associated with a decrease ...

Scientists using living human brain tissue have shown for the first time how a toxic form of a protein linked to Alzheimer's ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease.

Please discuss the class and complete drug profile of amyloid-targeting therapies for Alzheimer disease, including their mechanisms of action, efficacy, and safety profiles.

The study focuses on how immune cells react to amyloid-beta (Aβ) plaques, a hallmark of Alzheimer's, and how this immune response differs from the reaction to bacterial toxins. "Bacteria cannot ...

Background High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary endpoints. Neither drug ...

At the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD), Promis Neurosciences Inc. presented the rational design of an Alzheimer’s ...

Although there are many outstanding questions about Alzheimer’s and a significant lack of effective drugs, scientists believe a protein called amyloid-beta plays an important role in the condition.

In the next few weeks, Eli Lilly will report the first clinical data on a drug that represents a new approach to the treatment of ... against pyroglutamate- amyloid beta (pGlu-Abeta), a target ...

Roche has reported preliminary results on its Alzheimer’s disease prospect ... by data on the first wave of successful anti-amyloid-beta antibodies. Roche is hoping to improve on those molecules ...

The litany of failed trials of amyloid-targeting drugs for Alzheimer's disease has added another verse, as Roche concedes that its crenezumab candidate was unable to slow cognitive decline in ...